JP2017520573A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520573A5
JP2017520573A5 JP2016575190A JP2016575190A JP2017520573A5 JP 2017520573 A5 JP2017520573 A5 JP 2017520573A5 JP 2016575190 A JP2016575190 A JP 2016575190A JP 2016575190 A JP2016575190 A JP 2016575190A JP 2017520573 A5 JP2017520573 A5 JP 2017520573A5
Authority
JP
Japan
Prior art keywords
seq
protein
immunogenic composition
cdtb
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016575190A
Other languages
English (en)
Japanese (ja)
Other versions
JP6688233B2 (ja
JP2017520573A (ja
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/064324 external-priority patent/WO2015197737A1/en
Publication of JP2017520573A publication Critical patent/JP2017520573A/ja
Publication of JP2017520573A5 publication Critical patent/JP2017520573A5/ja
Application granted granted Critical
Publication of JP6688233B2 publication Critical patent/JP6688233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016575190A 2014-06-25 2015-06-25 クロストリジウム・ディフィシル免疫原性組成物 Active JP6688233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1411306.2 2014-06-25
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB1411371.6 2014-06-26
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition
PCT/EP2015/064324 WO2015197737A1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020005532A Division JP2020100625A (ja) 2014-06-25 2020-01-17 クロストリジウム・ディフィシル免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2017520573A JP2017520573A (ja) 2017-07-27
JP2017520573A5 true JP2017520573A5 (enExample) 2018-07-12
JP6688233B2 JP6688233B2 (ja) 2020-04-28

Family

ID=53498986

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575190A Active JP6688233B2 (ja) 2014-06-25 2015-06-25 クロストリジウム・ディフィシル免疫原性組成物
JP2020005532A Pending JP2020100625A (ja) 2014-06-25 2020-01-17 クロストリジウム・ディフィシル免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020005532A Pending JP2020100625A (ja) 2014-06-25 2020-01-17 クロストリジウム・ディフィシル免疫原性組成物

Country Status (18)

Country Link
US (1) US20170218031A1 (enExample)
EP (2) EP3636278A3 (enExample)
JP (2) JP6688233B2 (enExample)
CN (1) CN106536544B (enExample)
BE (1) BE1022949B1 (enExample)
BR (1) BR112016030096B1 (enExample)
CA (1) CA2952118A1 (enExample)
CY (1) CY1122145T1 (enExample)
DK (1) DK3160500T3 (enExample)
ES (1) ES2749701T3 (enExample)
HR (1) HRP20191864T1 (enExample)
HU (1) HUE045936T2 (enExample)
LT (1) LT3160500T (enExample)
MX (1) MX374380B (enExample)
PL (1) PL3160500T3 (enExample)
PT (1) PT3160500T (enExample)
SI (1) SI3160500T1 (enExample)
WO (1) WO2015197737A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595709A4 (en) * 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
JP7426953B2 (ja) 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
NZ263538A (en) 1993-03-23 1996-10-28 Smithkline Beecham Biolog Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11506332A (ja) 1995-06-02 1999-06-08 インサイト・ファーマスーティカルズ・インコーポレイテッド 全長cDNA配列を獲得する改良された方法
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
IN2014CN04071A (enExample) * 2011-12-08 2015-10-23 Novartis Ag
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Similar Documents

Publication Publication Date Title
JP2016504993A5 (enExample)
JP6199036B2 (ja) 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
JP2008530245A5 (enExample)
CN115175696A (zh) 包含白喉毒素交叉反应物质(crm)氨基酸序列的蛋白颗粒及其用途
RU2016111934A (ru) Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
ES2633299T3 (es) Polipéptidos inmunogénicos, los cuales comprenden un péptido matriz y un polipéptido L2, o un fragmento de éste
RU2008150400A (ru) Новая детерминанта вирулентности в пределах структурного гликопротеина е2 вируса классической лихорадки свиней
US12053520B2 (en) Glycan-masked engineered outer domains of HIV-1 gp120 and their use
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
JP2009520758A5 (enExample)
Su et al. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
JP2018500878A5 (enExample)
CA3211083A1 (en) Compositions including sbi adjuvants and methods of use thereof
TW201706296A (zh) 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物
JP2017520573A5 (enExample)
JP2015529677A5 (enExample)
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
Fernández et al. Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine
JP2009500037A (ja) Haemophilusinfluenzae誘発性疾患のためのキメラワクチン
Taherkhani et al. Cloning of FliC gene from Salmonella typhimurium in the expression vector pVAX1 and evaluation of its expression in eukaryotic cells
US20250064918A1 (en) Nipah henipavirus virus replicon particles and their use
RU2850338C2 (ru) Композиции, содержащие адъюванты sbi, и способы их применения
JP2025529904A (ja) Sars-cov-2免疫原性組成物および方法
HK40081102A (en) Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
JP2025532934A (ja) 組み合わせエクソソーム免疫原性組成物および方法